08 December 2023: Clinical Research
Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer
Wei Tao 1DEF* , Weiqi Wang 1CDF , Jingfang Zhai 2BCF , Linlin Guo 1ABFDOI: 10.12659/MSM.940545
Med Sci Monit 2023; 29:e940545
Table 2 Response to neoadjuvant chemotherapy for patients in the NT cohort.
| Type of response | Numbers of patients |
|---|---|
| Total number of patients | 105 |
| Complete response | 31 (30) |
| Partial response | 49 (47) |
| Progressive disease | 8 (8) |
| Stable disease | 17 (15) |
| Parameters are depicted as frequencies (percentages). Complete response: The absence of tumor cells and lymph nodes in pathology. Partial response:≥30% decrease in the sum of the longest diameter of the tumor in size. Progressive disease: ≥20% increase in the sum of longest diameters with an absolute increase of ≥5 mm, or detection of new lesions in pathology. Stable disease: neither partial response nor progressive disease. RECIST v1.1 was used to evaluate the response. Response was evaluated after neoadjuvant chemotherapy and before radical hysterectomy. | |